Comments on: Thermostabilization of PPR Live Vaccine re-visited

By: VRiitho

VRiitho — Thu, 14 May 2015 09:12:35 +0000

The Kenya Veterinary Vaccines Production unit is currently rolling out a lyophilised PPR vaccine (Pestevax) that has considerable demand in Kenya and the broader region. I think they could benefit immensely from improved yields of vaccine virus, an improved thermostable formulation, and a means of quality control (moisture content and virus stability analyses). The availability at ILRI of a state of the art lyophilizer, moisture content analysis equipment, improved cell lines for PPRV culture and a biodigester capable of improving virus yields compared to current methods makes this a promising venture that is likely to result in the availability of an improved vaccine in the market.

By: Dirk Hoekstra

Dirk Hoekstra — Thu, 14 May 2015 06:49:04 +0000

We had the testing of the thermo stable PPR vaccine in the LIVES project proposal. Would very much like this to become reality.

By: Tim

Tim — Wed, 13 May 2015 13:20:48 +0000

This is a great proposal but such things need to be linked to estimates of impact – what is the burden of disease? What benefits could be gained by improved control, and by whom?

By: Jimmy Smith

Jimmy Smith — Tue, 12 May 2015 20:31:05 +0000

This idea appeals to me very much. Not only is it directly relevant to the important case of PPR but to the wide array of vaccines requiring a cold chain for delivery. It is my layman’s view that ILRI should develop a strong capability in thermostabilization so as to make more of the available vaccines, that are sitting on the shelf hardly used, more accessible to users. It is a capability that will help get new vaccines developed by ILRI into use. The need for cold chains is a major impediment to getting vaccines into wide spread use.